GlassScriptPhysician profile
Margaret E Wierman
NPI 1639269319
$35,766.94
in general payments reported to CMS, 2019-2025
6 companies · $8,140 in 2025
The $8,140 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,095 · 2020: $1,250 · 2021: $2,000 · 2022: $16K · 2023: $38.93 · 2024: $1,283 · 2025: $8,140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,140 · Travel and Lodging: $789 · Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,140.00 |
| Travel and Lodging | $788.61 |
| Food and Beverage | $533.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $26,274.24 | 2019-2025 | Sogroya |
| Neurocrine Biosciences, INC. | $6,242.70 | 2024-2025 | |
| Hra Pharma Rare Diseases | $2,000.00 | 2021 | |
| Pfizer INC. | $1,250.00 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Wierman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.